Lakefront Biotherapeutics NV (AMS:LKFT)
Netherlands · Delayed Price · Currency is EUR 23.26
+0.78 (3.47%)
Aug 7, 2026, 3:13 PM CET
AMS:LKFT Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,044 | 1,112 | 275.65 | 239.72 | 241.25 | 234.38 |
Revenue Growth | 262.17% | 303.50% | 14.99% | -0.63% | 2.93% | -50.97% |
Gross Profit Gross Profit Growth | 715.32 | 623.09 | -94.67 | -1.57 | -28.55 | -86.12 |
Operating Income Operating Income Growth | 630.28 | 535.28 | -187.1 | -85.11 | -131.06 | -171.57 |
Net Income Net Income Growth | 488.78 | 320.88 | 74.08 | 211.7 | -217.99 | -103.23 |
Earnings Per Share EPS Growth | 7.42 | 4.87 | 1.12 | 3.21 | -3.32 | -1.58 |
EPS Growth | - | 333.66% | -65.05% | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
United States of America United States of America Growth | 1,081 | 240.79 | 239.71 | 241.15 | 234.34 |
Europe Europe Growth | 31.1 | 34.86 | 0.02 | 0.1 | 0.04 |
Total Total Growth | 1,112 | 275.65 | 239.72 | 241.25 | 234.38 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,982 | 2,998 | 3,118 | 3,685 | 4,094 | 4,703 |
Total Debt Total Debt Growth | 6.44 | 6.92 | 11.72 | 9.6 | 21.9 | 26.86 |
Net Cash (Debt) Net Cash Growth | 2,976 | 2,991 | 3,106 | 3,675 | 4,072 | 4,676 |
Net Cash Growth | -9.45% | -3.69% | -15.48% | -9.75% | -12.92% | -8.88% |
Net Cash Per Share Net Cash Per Share Growth | 45.15 | 45.39 | 47.10 | 55.74 | 61.98 | 71.39 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -301.6 | -257.46 | -320.03 | -405.97 | -500.54 | -503.83 |
Capital Expenditures CapEx Growth | -8.73 | -13.7 | -16.72 | -18.71 | -27.39 | -54.21 |
Free Cash Flow Free Cash Flow Growth | -310.33 | -271.16 | -336.75 | -424.68 | -527.93 | -558.03 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 68.53% | 56.02% | -34.34% | -0.66% | -11.83% | -36.74% |
Operating Margin | 60.39% | 48.13% | -67.87% | -35.50% | -54.32% | -73.20% |
Pretax Margin | 45.14% | 27.05% | -1.12% | 2.35% | -29.37% | -50.94% |
Profit Margin | 46.83% | 28.85% | 26.88% | 88.31% | -90.36% | -44.04% |
FCF Margin | -29.73% | -24.38% | -122.16% | -177.15% | -218.83% | -238.09% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 3.04 | 5.75 | 23.59 | 11.51 | - | - |
Forward PE | - | 128.80 | 128.80 | 128.80 | 128.80 | 128.80 |
PS Ratio | 1.42 | 1.66 | 6.34 | 10.17 | 11.28 | 13.77 |